Patients with early-onset T2DM should have more stringent glycemic management, with early use of hypoglycemic agents with cardio-renal benefits such as Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) and Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.